[1]陈铁桥,易小明,王 云,等.弥漫大B 细胞淋巴瘤患者病理组织中IQGAP2 和CDC42 表达及临床价值研究[J].现代检验医学杂志,2023,38(03):72-78.[doi:10.3969/j.issn.1671-7414.2023.03.013]
　CHEN Tie-qiao,YI Xiao-ming,WANG Yun,et al.Study on the Expression and Clinical Value of IQGAP2 and CDC42 in Pathological Tissues of Patients with Diffuse Large B-cell Lymphoma[J].Journal of Modern Laboratory Medicine,2023,38(03):72-78.[doi:10.3969/j.issn.1671-7414.2023.03.013]
点击复制

弥漫大B 细胞淋巴瘤患者病理组织中IQGAP2 和CDC42 表达及临床价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年03期
页码:
72-78
栏目:
论著
出版日期:
2023-05-15

文章信息/Info

Title:
Study on the Expression and Clinical Value of IQGAP2 and CDC42 in Pathological Tissues of Patients with Diffuse Large B-cell Lymphoma
文章编号:
1671-7414（2023）03-072-07
作者:
陈铁桥1; 易小明1; 王 云2; 王明明1; 张雨相1
（1. 湖南中医药高等专科学校附属第一医院/ 湖南省直中医医院检验科，湖南株洲 412000； 2. 岳阳市中医医院检验科，湖南岳阳 414021）
Author(s):
CHEN Tie-qiao1; YI Xiao-ming1; WANG Yun2; WANG Ming-ming1; ZHANG Yu-xiang1
（1. Department of Clinical Laboratory, the First Affiliated Hospital of Hunan College of Traditional Chinese Medicine / Hunan Provincial Hospital of Traditional Chinese Medicine, Hunan Zhuzhou 412000, China；2. Department of Clinical Laboratory, Yueyang Tr
关键词:
弥漫大B 细胞淋巴瘤; 含有IQ 基序的GTPase 激活蛋白2; 细胞分裂周期蛋白42
分类号:
R733.4；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.03.013
文献标志码:
A
摘要:
目的 研究弥漫大B 细胞淋巴瘤（iffuse large B-cell lymphoma，DLBCL）患者病理组织中含有IQ 基序GTPase激活蛋白2（IQ motif containing GTPase activating protein 2，IQGAP2）和细胞分裂周期蛋白42(cell division cycle 42，CDC42) 的表达及临床意义。方法 选取2017 年2 月～ 2019 年2 月期间湖南省直中医医院诊治的83 例初诊DLBCL患者为研究对象，以同期诊治的50 例反应性淋巴结增生（reactive lymph node hyperplasia，RHL）患者为RLH 组。应用免疫组织化学法及免疫印迹法检测组织中IQGAP2 和CDC42 的表达。比较不同临床病理特征患者DLBCL 组织中IQGAP2 和CDC42 的表达差异。Kaplan-Meier 生存分析IQGAP2 和CDC42 表达对DLBCL 患者生存预后的影响。单因素和多因素COX 回归分析影响DLBCL 患者预后的因素。结果 DLBCL 组中IQGAP2（83.13%），CDC42（85.54%）蛋白阳性率高于RLH 组（8.00%，12.00%），差异均有统计学意义（χ2=57.016，69.230，均P <0.05）。DLBCL 组织中IQGAP2（1.21±0.23 ），CDC42（1.34±0.25）蛋白相对表达量高于RLH 组织（0.61±0.18，0.75±0.21），差异具有统计学意义（t=15.759，14.377，均P<0.05）。Hans 分型非GCB 型，Ann Arbor 临床分期Ⅲ～Ⅳ期组织中IQGAP2（90.00% vs 69.70%，91.67% vs 71.43%），CDC42（92.00% vs 75.76%，93.75% vs 74.29%）蛋白阳性率大于GCB 型，Ⅰ～Ⅱ期，差异具有统计学意义（t=4.241 ～ 6.200，均P <0.05）。IQGAP2 阳性组（50.72% vs 85.71%），CDC42 阳性组（50.70% vs 91.67%）完全缓解率分别低于IQGAP2 阴性组，CDC42 阴性组，差异具有统计学意义（χ2=5.801，7.013，均P<0.05）。IQGAP2 阳性组（56.52% vs 85.71%），CDC42 阳性组（56.34% vs 91.67%）三年总体生存率分别低于IQGAP2 阴性组和CDC42 阴性组患者，差异均有统计学意义（χ2=4.318，4.963，均P<0.05）。Ann Arbor 分期Ⅲ～Ⅳ期（OR=1.618，95%CI：1.019 ～ 2.569），IQGAP2 阳性（OR=2.036，95%CI：1.174 ～ 3.532），CDC42 阳性（OR=1.763，95%CI：1.114 ～ 2.789）是影响DLBCL 患者生存预后的独立危险因素。结论 DLBCL 组织中IQGAP2，CDC42 表达升高，是影响DLBCL 患者不良预后的独立因素，是新的DLBCL 肿瘤标志物。
Abstract:
Objective To study the expression and clinical significance of GTPase-activating protein 2 (IQGAP2) and mitotic cyclin 42 (CDC42) in the pathological tissues of patients with diffuse large B-cell lymphoma (DLBCL). Methods A total of 83 newly diagnosed DLBCL patients diagnosed and treated in Hunan Provincial Directly Affiliated of Traditional Chinese Medicine Hospital from February 2017 to February 2019 were selected as the research objects, 50 patients with reactive lymph node hyperplasia diagnosed and treated at the same time were taken as RLH group. The expressions of IQGAP2 and CDC42 in tissues were detected by immunohistochemistry and immunoblotting. The expression differences of IQGAP2 and CDC42 in DLBCL tissues of patients with different clinicopathological characteristics were compared. The effects of IQGAP2 and CDC42 expression on survival prognosis of DLBCL patients were analyzed by Kaplan-Meier survival analysis. Univariate and multivariate COX regression analysis were used to analyze factors affecting the prognosis of DLBCL patients. Results The positive rate of IQGAP2 (83.13%) and CDC42 (85.54%) protein in DLBCL group were higher than that in RLH group（8.00%， 12.00%）, the differences were statistically significant（χ2=57.016, 69.230，all P<0.05). The relative expression of IQGAP2 (1.21 ± 0.23) and CDC42 (1.34 ± 0.25) protein bands in DLBCL tissue was higher than that in RLH tissue （0.61±0.18， 0.75±0.21），and the differences were statistically significant (t=15.759, 14.377, all P<0.05). The positive rate of IQGAP2 (90.00% vs 69.70%, 91.67% vs 71.43%) and CDC42 (92.00% vs 75.76%, 93.75% vs 74.29%) in not GCB Hans type, Ann Arbor clinical stage III to IV were higher than that of GCB type, stage I to II, with statistically significant difference (t=4.241 ～ 6.200, all P<0.05). The complete remission rate of IQGAP2 (50.72% vs 85.71%) and CDC42 (50.70% vs 91.67%) positive group were significantly lower than that of IQGAP2 and CDC42 negative group, respectively（χ2=5.801, 7.013, all P<0.05). The 3-year overall survival rate of IQGAP2 (56.52% vs 85.71%), CDC42 (56.34% vs 91.67%) positive group were significantly lower than that of IQGAP2, and CDC42 negative group, and the differernces were statistically significant(χ2=4.318, 4.963, all P<0.05). IQGAP2 positive (OR=2.036, 95% CI ：1.174 ～ 3.532) and CDC42 positive (OR=1.763, 95% CI：1.114 ～2.789) were independent risk factors affecting the survival and prognosis of patients with DLBCL. Conclusion The increased expression of IQGAP2 and CDC42 in DLBCL tissue are independent factors affecting the poor prognosis of DLBCL patients and are new DLBCL tumor marker.

参考文献/References:

[1] ZELENETZ A D, GORDON L I, ABRAMSON J S, et al. NCCN guidelines insights: B-cell lymphomas, Version 3.2019[J]. Journal of the National Comprehensive Cancer Network, 2019, 17(6)：650-661.
[2] 陈思言, 张伶莉, 杨丽华. 弥漫性大B 细胞淋巴瘤 组织中miR-448 和KDM2B 的水平表达及临床意义 [J]. 现代检验医学杂志, 2022, 37（4）：128-133. CHEN Siyan, ZHANG Lingli, YANG Lihua. Expression levels and clinical significance of miR- 448 and KDM2B in diffuse large B-cell lymphoma tissues[J]. Journal of Modern Laboratory Medicine,2022, 37(4): 128-133.
[3] ZHANG Li, YANG Shengye, QI-LI Fengrong,et al. Administration of isoliquiritigenin prevents nonalcoholic fatty liver disease through a novel IQGAP2-CREB-SIRT1 axis[J]. Phytotherapy Research,2021, 35(7): 3898-3915.
[4] WANG Daoliang, WANG Zhuo, ZHANG Lijun, et al. LncRNA PDCD4-AS1 alleviates triple negative breast cancer by increasing expression of IQGAP2 via miR-10b-5p[J]. Translational Oncology, 2021, 14(1): 100958.
[5] XIE Yanyun, ZHENG Linfeng, TAO Li j ian. Downregulation of IQGAP2 correlates with prostate cancer recurrence and metastasis[J]. Translational Oncology, 2019, 12(2): 236-244.
[6] ZHANG Yu, LI Jun, LAI Xingning, et al. Focus on CDC42 in breast cancer: new insights, target therapy development and non-coding RNAs[J]. Cells, 2019,8(2): 146.
[7] ZHU Zhonglin, YU Zhilong, RONG Zeyin, et al. The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42[J]. Theranostics, 2019, 9(26): 8294-8311.
[8] CHESON B D, HORNING S J, COIFFIER B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J]. Journal of Clinical Oncology, 1999, 17(4): 1244-1257.
[9] 薛妞艳, 孙凤玲, 刘文博. 弥漫大B 细胞淋巴瘤骨 髓侵犯的异质性与病理特征[J]. 中国肿瘤临床与康 复, 2019, 26(2): 1448-1451. XUE Niuyan, SUN Fengling, LIU Wenbo. Heterogeneity and pathological features of bone marrow invasion in diffuse large B-cell lymphoma[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2019,26(12): 1448-1451.
[10] CHAPUY B, STEWART C, DUNFORD A J, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes[J]. Nature Medicine, 2018, 24(5): 679-690.
[11] KUMAR D, PATEL S A, HASSAN M K, et al. Reduced IQGAP2 expression promotes EMT and inhibits apoptosis by modulating the MEK-ERK and p38 signaling in breast cancer irrespective of ER status[J]. Cell Death Dis, 2021, 12(4): 389.
[12] 刘飞能, 夏成兴, 欧译天, 等. 支架蛋白家族IQGAP 在肿瘤中的生物学功能研究进展[J]. 生物技术通讯,2020, 31(6): 775-780. LIU Feineng, XIA Chengxing, OU Yitian, et al.Research progress on the biological function of scaffold protein family IQGAP in tumor[J]. Letters in Biotechnology, 2020, 31(6): 775-780.
[13] TANG Tianjiao, WANG Jing, ZHANG Lidan, et al. IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL[J]. BMC Cancer, 2021, 21(1): 603.
[14] SONG Fei, KOTOLLOSHI R, GAJDA M, et al. Reduced IQGAP2 promotes bladder cancer through regulation of MAPK/ERK pathway and cytokines[J]. International Journal of Molecular Sciences, 2022,23(21): 13508.
[15] KUMAR D, PATEL S A, KHAN R, et al. IQ motifcontaining GTPase-activating protein 2 inhibits breast cancer angiogenesis by suppressing VEGFR2-AKT signaling[J]. Molecular Cancer Research, 2022, 20(1): 77-91.
[16] MURPHY N P, BINTI AHMAD MOKHTAR A M, MOTT H R, et al. Molecular subversion of CDC42 signalling in cancer[J]. Biochemical Society Transactions, 2021, 49(3): 1425-1442.
[17] MILLER K E, KANG P J, PARK H O. Regulation of Cdc42 for polarized growth in budding yeast[J]. Microbial Cell, 2020, 7(7): 175-189.
[18] RAMOS-?LVAREZ I, LEE L, JENSEN R T. Group II p21-activated kinase, PAK4, is needed for activation of focal adhesion kinases, MAPK, GSK3, and β-catenin in rat pancreatic acinar cells[J]. American Journal of Physiology Gastrointestinal and Liver Physiology,2020, 318(3): G490-G503.
[19] YAN Shushan, REN Xiaoxia, YANG Jinghan, et al. Exosomal miR-548c-5p regulates colorectal cancer cell growth and invasion through HIF1A/CDC42 axis[J]. OncoTargets and Therapy, 2020, 13: 9875-9885.
[20] NGUYEN P, CHAKRABARTI J, LI Yuan, et al. Rational targeting of CDC42 overcomes drug resistance of multiple myeloma[J]. Frontiers in Oncology, 2019, 9: 958.

备注/Memo

备注/Memo:
基金项目： 湖南省自然科学基金项目（编号：2019JJ80064）：弥漫大B 细胞淋巴瘤中含有IQ 基序GTPase 激活蛋白2，细胞分裂周期蛋白42 的表达。
作者简介：陈铁桥（1990-），男，硕士，主管检验师，从事细胞形态学、临床病理检验诊断研究，E-mail：chentieqiao1990@163.com。
更新日期/Last Update: 2023-05-15